nodes	percent_of_prediction	percent_of_DWPC	metapath
Dopamine—SLC22A3—Irinotecan—lung cancer	0.111	0.207	CbGbCtD
Dopamine—SLC22A2—Vinblastine—lung cancer	0.0585	0.109	CbGbCtD
Dopamine—SLC22A2—Cisplatin—lung cancer	0.0536	0.0997	CbGbCtD
Dopamine—CYP2C19—Gefitinib—lung cancer	0.0407	0.0756	CbGbCtD
Dopamine—CYP2C19—Teniposide—lung cancer	0.0394	0.0733	CbGbCtD
Dopamine—CYP2C9—Gefitinib—lung cancer	0.0338	0.0628	CbGbCtD
Dopamine—CYP2C9—Teniposide—lung cancer	0.0328	0.0609	CbGbCtD
Dopamine—CYP2D6—Gefitinib—lung cancer	0.0309	0.0575	CbGbCtD
Dopamine—CYP2D6—Vinorelbine—lung cancer	0.0238	0.0443	CbGbCtD
Dopamine—CYP1A2—Erlotinib—lung cancer	0.0222	0.0412	CbGbCtD
Dopamine—CYP2C9—Paclitaxel—lung cancer	0.0183	0.034	CbGbCtD
Dopamine—CYP2D6—Erlotinib—lung cancer	0.0183	0.034	CbGbCtD
Dopamine—CYP1A2—Etoposide—lung cancer	0.016	0.0298	CbGbCtD
Dopamine—CYP2C9—Cisplatin—lung cancer	0.0147	0.0274	CbGbCtD
Dopamine—CYP2D6—Vinblastine—lung cancer	0.0147	0.0273	CbGbCtD
Dopamine—Piloerection—Irinotecan—lung cancer	0.00949	0.0761	CcSEcCtD
Dopamine—CYP2D6—Doxorubicin—lung cancer	0.00902	0.0168	CbGbCtD
Dopamine—Gangrene—Gemcitabine—lung cancer	0.00734	0.0589	CcSEcCtD
Dopamine—HTR7—pulmonary artery—lung cancer	0.00625	0.134	CbGeAlD
Dopamine—Cyanosis—Teniposide—lung cancer	0.00445	0.0356	CcSEcCtD
Dopamine—Masoprocol—IGF1R—lung cancer	0.00425	0.818	CrCbGaD
Dopamine—Extravasation—Teniposide—lung cancer	0.00361	0.0289	CcSEcCtD
Dopamine—Atrial fibrillation—Gefitinib—lung cancer	0.00296	0.0237	CcSEcCtD
Dopamine—Extravasation—Vinblastine—lung cancer	0.00275	0.0221	CcSEcCtD
Dopamine—Extravasation—Topotecan—lung cancer	0.00267	0.0214	CcSEcCtD
Dopamine—Necrosis—Vinorelbine—lung cancer	0.00254	0.0204	CcSEcCtD
Dopamine—Angina pectoris—Pemetrexed—lung cancer	0.00238	0.019	CcSEcCtD
Dopamine—Extravasation—Vinorelbine—lung cancer	0.00229	0.0183	CcSEcCtD
Dopamine—Bradycardia—Crizotinib—lung cancer	0.00217	0.0174	CcSEcCtD
Dopamine—Cyanosis—Etoposide—lung cancer	0.00193	0.0155	CcSEcCtD
Dopamine—Necrosis—Cisplatin—lung cancer	0.0019	0.0153	CcSEcCtD
Dopamine—Extravasation—Irinotecan—lung cancer	0.00189	0.0151	CcSEcCtD
Dopamine—Extravasation—Gemcitabine—lung cancer	0.00184	0.0147	CcSEcCtD
Dopamine—Necrosis—Etoposide—lung cancer	0.00174	0.014	CcSEcCtD
Dopamine—Extravasation—Cisplatin—lung cancer	0.00171	0.0137	CcSEcCtD
Dopamine—Necrosis—Paclitaxel—lung cancer	0.00171	0.0137	CcSEcCtD
Dopamine—DBH—bone marrow—lung cancer	0.00168	0.036	CbGeAlD
Dopamine—Extrasystoles—Paclitaxel—lung cancer	0.0016	0.0128	CcSEcCtD
Dopamine—Extravasation—Etoposide—lung cancer	0.00157	0.0126	CcSEcCtD
Dopamine—Azotaemia—Methotrexate—lung cancer	0.00154	0.0123	CcSEcCtD
Dopamine—Extravasation—Paclitaxel—lung cancer	0.00154	0.0123	CcSEcCtD
Dopamine—COMT—respiratory system—lung cancer	0.00151	0.0325	CbGeAlD
Dopamine—Angina pectoris—Vinblastine—lung cancer	0.00147	0.0118	CcSEcCtD
Dopamine—Hypertension—Pemetrexed—lung cancer	0.00147	0.0118	CcSEcCtD
Dopamine—Necrosis—Docetaxel—lung cancer	0.00145	0.0116	CcSEcCtD
Dopamine—SLC22A5—mammary gland—lung cancer	0.00139	0.0298	CbGeAlD
Dopamine—Dyspnoea—Crizotinib—lung cancer	0.00135	0.0108	CcSEcCtD
Dopamine—SLC6A3—respiratory system—lung cancer	0.00135	0.029	CbGeAlD
Dopamine—Extravasation—Docetaxel—lung cancer	0.0013	0.0105	CcSEcCtD
Dopamine—COMT—bronchus—lung cancer	0.00125	0.0267	CbGeAlD
Dopamine—SLC6A4—respiratory system—lung cancer	0.00124	0.0266	CbGeAlD
Dopamine—Dyspnoea—Pemetrexed—lung cancer	0.00124	0.00991	CcSEcCtD
Dopamine—Dyspnoea—Gefitinib—lung cancer	0.00123	0.00984	CcSEcCtD
Dopamine—Angina pectoris—Vinorelbine—lung cancer	0.00122	0.00978	CcSEcCtD
Dopamine—CYP2C9—mammary gland—lung cancer	0.00119	0.0256	CbGeAlD
Dopamine—Hypertension—Teniposide—lung cancer	0.00119	0.00952	CcSEcCtD
Dopamine—MAOB—respiratory system—lung cancer	0.00118	0.0253	CbGeAlD
Dopamine—Cyanosis—Methotrexate—lung cancer	0.00116	0.00929	CcSEcCtD
Dopamine—COMT—trachea—lung cancer	0.00112	0.024	CbGeAlD
Dopamine—Tachycardia—Teniposide—lung cancer	0.0011	0.00878	CcSEcCtD
Dopamine—SLC6A2—respiratory system—lung cancer	0.00109	0.0234	CbGeAlD
Dopamine—ADRB1—bronchus—lung cancer	0.00106	0.0226	CbGeAlD
Dopamine—HTR7—respiratory system—lung cancer	0.00105	0.0226	CbGeAlD
Dopamine—COMT—cardiac atrium—lung cancer	0.00105	0.0225	CbGeAlD
Dopamine—Necrosis—Methotrexate—lung cancer	0.00104	0.00837	CcSEcCtD
Dopamine—DBH—lymph node—lung cancer	0.00104	0.0223	CbGeAlD
Dopamine—Atrial fibrillation—Paclitaxel—lung cancer	0.00103	0.00824	CcSEcCtD
Dopamine—Angina pectoris—Irinotecan—lung cancer	0.00101	0.00806	CcSEcCtD
Dopamine—MAOA—respiratory system—lung cancer	0.00101	0.0216	CbGeAlD
Dopamine—Dyspnoea—Teniposide—lung cancer	0.001	0.00802	CcSEcCtD
Dopamine—DRD2—respiratory system—lung cancer	0.000994	0.0213	CbGeAlD
Dopamine—MAOB—bronchus—lung cancer	0.00097	0.0208	CbGeAlD
Dopamine—Vomiting—Crizotinib—lung cancer	0.000965	0.00773	CcSEcCtD
Dopamine—Ventricular arrhythmia—Doxorubicin—lung cancer	0.000959	0.00769	CcSEcCtD
Dopamine—Extravasation—Methotrexate—lung cancer	0.00094	0.00753	CcSEcCtD
Dopamine—SLC22A5—respiratory system—lung cancer	0.000926	0.0199	CbGeAlD
Dopamine—Hypertension—Vinblastine—lung cancer	0.000906	0.00726	CcSEcCtD
Dopamine—Necrosis—Doxorubicin—lung cancer	0.000905	0.00725	CcSEcCtD
Dopamine—Nausea—Crizotinib—lung cancer	0.000901	0.00722	CcSEcCtD
Dopamine—ADRB1—cardiac atrium—lung cancer	0.00089	0.0191	CbGeAlD
Dopamine—COMT—bone marrow—lung cancer	0.000887	0.019	CbGeAlD
Dopamine—Vomiting—Pemetrexed—lung cancer	0.000882	0.00707	CcSEcCtD
Dopamine—HTR7—epithelium—lung cancer	0.000879	0.0188	CbGeAlD
Dopamine—Vomiting—Gefitinib—lung cancer	0.000876	0.00702	CcSEcCtD
Dopamine—Atrial fibrillation—Docetaxel—lung cancer	0.000872	0.00699	CcSEcCtD
Dopamine—Anxiety—Erlotinib—lung cancer	0.000856	0.00686	CcSEcCtD
Dopamine—Bradycardia—Irinotecan—lung cancer	0.000842	0.00674	CcSEcCtD
Dopamine—CYP1A2—respiratory system—lung cancer	0.000839	0.018	CbGeAlD
Dopamine—MAOA—bronchus—lung cancer	0.000827	0.0177	CbGeAlD
Dopamine—Nausea—Pemetrexed—lung cancer	0.000824	0.0066	CcSEcCtD
Dopamine—Nausea—Gefitinib—lung cancer	0.000818	0.00656	CcSEcCtD
Dopamine—MAOB—cardiac atrium—lung cancer	0.000818	0.0175	CbGeAlD
Dopamine—Extravasation—Doxorubicin—lung cancer	0.000814	0.00652	CcSEcCtD
Dopamine—COMT—lung—lung cancer	0.000804	0.0172	CbGeAlD
Dopamine—HTR7—trachea—lung cancer	0.000777	0.0167	CbGeAlD
Dopamine—Palpitations—Vinorelbine—lung cancer	0.000771	0.00618	CcSEcCtD
Dopamine—Bradycardia—Cisplatin—lung cancer	0.000764	0.00612	CcSEcCtD
Dopamine—SLC22A5—bronchus—lung cancer	0.000762	0.0163	CbGeAlD
Dopamine—Hypertension—Vinorelbine—lung cancer	0.000753	0.00604	CcSEcCtD
Dopamine—MAOA—trachea—lung cancer	0.000743	0.0159	CbGeAlD
Dopamine—Dyspnoea—Topotecan—lung cancer	0.000742	0.00595	CcSEcCtD
Dopamine—Dyspnoea—Erlotinib—lung cancer	0.000734	0.00588	CcSEcCtD
Dopamine—SLC6A3—lung—lung cancer	0.000718	0.0154	CbGeAlD
Dopamine—Vomiting—Teniposide—lung cancer	0.000714	0.00572	CcSEcCtD
Dopamine—Headache—Teniposide—lung cancer	0.000704	0.00564	CcSEcCtD
Dopamine—MAOA—cardiac atrium—lung cancer	0.000698	0.015	CbGeAlD
Dopamine—Angina pectoris—Docetaxel—lung cancer	0.000695	0.00557	CcSEcCtD
Dopamine—Tachycardia—Vinorelbine—lung cancer	0.000695	0.00557	CcSEcCtD
Dopamine—Bradycardia—Paclitaxel—lung cancer	0.000686	0.0055	CcSEcCtD
Dopamine—SLC22A5—trachea—lung cancer	0.000684	0.0147	CbGeAlD
Dopamine—ADRB1—lung—lung cancer	0.000681	0.0146	CbGeAlD
Dopamine—SLC22A3—lung—lung cancer	0.000676	0.0145	CbGeAlD
Dopamine—Nausea—Teniposide—lung cancer	0.000667	0.00535	CcSEcCtD
Dopamine—SLC6A4—lung—lung cancer	0.000658	0.0141	CbGeAlD
Dopamine—SLC22A5—cardiac atrium—lung cancer	0.000643	0.0138	CbGeAlD
Dopamine—Dyspnoea—Vinorelbine—lung cancer	0.000635	0.00509	CcSEcCtD
Dopamine—MAOB—lung—lung cancer	0.000626	0.0134	CbGeAlD
Dopamine—Hypertension—Irinotecan—lung cancer	0.000621	0.00498	CcSEcCtD
Dopamine—Hypertension—Gemcitabine—lung cancer	0.000605	0.00485	CcSEcCtD
Dopamine—SLC6A2—lung—lung cancer	0.000579	0.0124	CbGeAlD
Dopamine—HTR7—lung—lung cancer	0.000558	0.012	CbGeAlD
Dopamine—Anxiety—Cisplatin—lung cancer	0.000554	0.00444	CcSEcCtD
Dopamine—COMT—lymph node—lung cancer	0.00055	0.0118	CbGeAlD
Dopamine—Vomiting—Vinblastine—lung cancer	0.000545	0.00437	CcSEcCtD
Dopamine—Headache—Vinblastine—lung cancer	0.000537	0.0043	CcSEcCtD
Dopamine—MAOA—lung—lung cancer	0.000534	0.0114	CbGeAlD
Dopamine—Vomiting—Topotecan—lung cancer	0.000529	0.00424	CcSEcCtD
Dopamine—DRD2—lung—lung cancer	0.000528	0.0113	CbGeAlD
Dopamine—Vomiting—Erlotinib—lung cancer	0.000524	0.0042	CcSEcCtD
Dopamine—Dyspnoea—Irinotecan—lung cancer	0.000524	0.0042	CcSEcCtD
Dopamine—Headache—Topotecan—lung cancer	0.000521	0.00418	CcSEcCtD
Dopamine—Tachycardia—Cisplatin—lung cancer	0.00052	0.00417	CcSEcCtD
Dopamine—Palpitations—Paclitaxel—lung cancer	0.000519	0.00416	CcSEcCtD
Dopamine—Hypertension—Etoposide—lung cancer	0.000517	0.00414	CcSEcCtD
Dopamine—Headache—Erlotinib—lung cancer	0.000516	0.00414	CcSEcCtD
Dopamine—Dyspnoea—Gemcitabine—lung cancer	0.00051	0.00409	CcSEcCtD
Dopamine—Nausea—Vinblastine—lung cancer	0.000509	0.00408	CcSEcCtD
Dopamine—Hypertension—Paclitaxel—lung cancer	0.000507	0.00406	CcSEcCtD
Dopamine—Anxiety—Paclitaxel—lung cancer	0.000498	0.00399	CcSEcCtD
Dopamine—Isoprenaline—CYP1A1—lung cancer	0.000495	0.0953	CrCbGaD
Dopamine—Nausea—Topotecan—lung cancer	0.000494	0.00396	CcSEcCtD
Dopamine—SLC22A5—lung—lung cancer	0.000492	0.0105	CbGeAlD
Dopamine—Nausea—Erlotinib—lung cancer	0.000489	0.00392	CcSEcCtD
Dopamine—Tachycardia—Etoposide—lung cancer	0.000477	0.00382	CcSEcCtD
Dopamine—Dyspnoea—Cisplatin—lung cancer	0.000475	0.00381	CcSEcCtD
Dopamine—Tachycardia—Paclitaxel—lung cancer	0.000467	0.00375	CcSEcCtD
Dopamine—SLC22A3—lymph node—lung cancer	0.000462	0.00992	CbGeAlD
Dopamine—Vomiting—Vinorelbine—lung cancer	0.000453	0.00363	CcSEcCtD
Dopamine—Mesalazine—PTGS2—lung cancer	0.000452	0.0869	CrCbGaD
Dopamine—Headache—Vinorelbine—lung cancer	0.000446	0.00358	CcSEcCtD
Dopamine—CYP1A2—lung—lung cancer	0.000445	0.00955	CbGeAlD
Dopamine—Palpitations—Docetaxel—lung cancer	0.00044	0.00352	CcSEcCtD
Dopamine—Dyspnoea—Etoposide—lung cancer	0.000436	0.00349	CcSEcCtD
Dopamine—Angina pectoris—Doxorubicin—lung cancer	0.000434	0.00348	CcSEcCtD
Dopamine—Hypertension—Docetaxel—lung cancer	0.000429	0.00344	CcSEcCtD
Dopamine—MAOB—lymph node—lung cancer	0.000428	0.00918	CbGeAlD
Dopamine—Dyspnoea—Paclitaxel—lung cancer	0.000427	0.00342	CcSEcCtD
Dopamine—Nausea—Vinorelbine—lung cancer	0.000423	0.00339	CcSEcCtD
Dopamine—Tachycardia—Docetaxel—lung cancer	0.000396	0.00318	CcSEcCtD
Dopamine—SLC6A2—lymph node—lung cancer	0.000396	0.0085	CbGeAlD
Dopamine—Vomiting—Irinotecan—lung cancer	0.000373	0.00299	CcSEcCtD
Dopamine—Headache—Irinotecan—lung cancer	0.000368	0.00295	CcSEcCtD
Dopamine—MAOA—lymph node—lung cancer	0.000365	0.00783	CbGeAlD
Dopamine—Vomiting—Gemcitabine—lung cancer	0.000364	0.00292	CcSEcCtD
Dopamine—Bradycardia—Doxorubicin—lung cancer	0.000363	0.00291	CcSEcCtD
Dopamine—Dyspnoea—Docetaxel—lung cancer	0.000362	0.0029	CcSEcCtD
Dopamine—Headache—Gemcitabine—lung cancer	0.000358	0.00287	CcSEcCtD
Dopamine—Nausea—Irinotecan—lung cancer	0.000349	0.0028	CcSEcCtD
Dopamine—Nausea—Gemcitabine—lung cancer	0.00034	0.00272	CcSEcCtD
Dopamine—Vomiting—Cisplatin—lung cancer	0.000339	0.00272	CcSEcCtD
Dopamine—SLC22A5—lymph node—lung cancer	0.000336	0.00721	CbGeAlD
Dopamine—Nausea—Cisplatin—lung cancer	0.000317	0.00254	CcSEcCtD
Dopamine—Vomiting—Etoposide—lung cancer	0.000311	0.00249	CcSEcCtD
Dopamine—Headache—Etoposide—lung cancer	0.000306	0.00245	CcSEcCtD
Dopamine—Vomiting—Paclitaxel—lung cancer	0.000305	0.00244	CcSEcCtD
Dopamine—Headache—Paclitaxel—lung cancer	0.0003	0.0024	CcSEcCtD
Dopamine—Nausea—Etoposide—lung cancer	0.00029	0.00233	CcSEcCtD
Dopamine—Nausea—Paclitaxel—lung cancer	0.000284	0.00228	CcSEcCtD
Dopamine—Palpitations—Doxorubicin—lung cancer	0.000274	0.0022	CcSEcCtD
Dopamine—Hypertension—Doxorubicin—lung cancer	0.000268	0.00215	CcSEcCtD
Dopamine—Anxiety—Doxorubicin—lung cancer	0.000263	0.00211	CcSEcCtD
Dopamine—Dyspnoea—Methotrexate—lung cancer	0.000261	0.00209	CcSEcCtD
Dopamine—Vomiting—Docetaxel—lung cancer	0.000258	0.00207	CcSEcCtD
Dopamine—Headache—Docetaxel—lung cancer	0.000254	0.00204	CcSEcCtD
Dopamine—Tachycardia—Doxorubicin—lung cancer	0.000247	0.00198	CcSEcCtD
Dopamine—Nausea—Docetaxel—lung cancer	0.000241	0.00193	CcSEcCtD
Dopamine—Dyspnoea—Doxorubicin—lung cancer	0.000226	0.00181	CcSEcCtD
Dopamine—Vomiting—Methotrexate—lung cancer	0.000186	0.00149	CcSEcCtD
Dopamine—Headache—Methotrexate—lung cancer	0.000183	0.00147	CcSEcCtD
Dopamine—Nausea—Methotrexate—lung cancer	0.000174	0.00139	CcSEcCtD
Dopamine—Vomiting—Doxorubicin—lung cancer	0.000161	0.00129	CcSEcCtD
Dopamine—Headache—Doxorubicin—lung cancer	0.000159	0.00127	CcSEcCtD
Dopamine—Nausea—Doxorubicin—lung cancer	0.00015	0.00121	CcSEcCtD
Dopamine—DRD3—GPCR downstream signaling—AKT1—lung cancer	5.56e-06	1.95e-05	CbGpPWpGaD
Dopamine—DRD4—Signaling Pathways—EP300—lung cancer	5.56e-06	1.95e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling Pathways—IL6R—lung cancer	5.55e-06	1.95e-05	CbGpPWpGaD
Dopamine—DRD1—Signaling by GPCR—IL6—lung cancer	5.55e-06	1.94e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling Pathways—CREBBP—lung cancer	5.55e-06	1.94e-05	CbGpPWpGaD
Dopamine—ADRB1—Signaling Pathways—ERBB2—lung cancer	5.53e-06	1.94e-05	CbGpPWpGaD
Dopamine—DRD3—Signaling Pathways—CASP3—lung cancer	5.51e-06	1.93e-05	CbGpPWpGaD
Dopamine—DRD3—Signaling Pathways—IL2—lung cancer	5.5e-06	1.93e-05	CbGpPWpGaD
Dopamine—HTR7—Signaling Pathways—VEGFA—lung cancer	5.5e-06	1.93e-05	CbGpPWpGaD
Dopamine—DRD3—Signaling by GPCR—IL6—lung cancer	5.47e-06	1.92e-05	CbGpPWpGaD
Dopamine—ADRB1—Signaling Pathways—MTOR—lung cancer	5.46e-06	1.91e-05	CbGpPWpGaD
Dopamine—ADRB1—Signaling Pathways—PIK3CB—lung cancer	5.46e-06	1.91e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling by GPCR—EGFR—lung cancer	5.45e-06	1.91e-05	CbGpPWpGaD
Dopamine—HTR7—Signaling Pathways—STAT3—lung cancer	5.44e-06	1.91e-05	CbGpPWpGaD
Dopamine—DRD1—Signaling Pathways—CCND1—lung cancer	5.43e-06	1.9e-05	CbGpPWpGaD
Dopamine—HTR7—Signaling Pathways—NRAS—lung cancer	5.43e-06	1.9e-05	CbGpPWpGaD
Dopamine—DRD1—Signaling Pathways—JUN—lung cancer	5.42e-06	1.9e-05	CbGpPWpGaD
Dopamine—DRD4—Signaling Pathways—SRC—lung cancer	5.4e-06	1.89e-05	CbGpPWpGaD
Dopamine—DRD5—Signaling Pathways—TP53—lung cancer	5.39e-06	1.89e-05	CbGpPWpGaD
Dopamine—HTR1A—Signaling by GPCR—PIK3CA—lung cancer	5.39e-06	1.89e-05	CbGpPWpGaD
Dopamine—SLC22A2—Metabolism—PTEN—lung cancer	5.37e-06	1.88e-05	CbGpPWpGaD
Dopamine—HTR1A—Signaling Pathways—MDM2—lung cancer	5.37e-06	1.88e-05	CbGpPWpGaD
Dopamine—DRD3—Signaling Pathways—CCND1—lung cancer	5.36e-06	1.88e-05	CbGpPWpGaD
Dopamine—DRD3—Signaling Pathways—JUN—lung cancer	5.35e-06	1.87e-05	CbGpPWpGaD
Dopamine—HTR1A—Signaling Pathways—RAF1—lung cancer	5.35e-06	1.87e-05	CbGpPWpGaD
Dopamine—CYP2D6—Metabolism—CYP1A1—lung cancer	5.33e-06	1.87e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling Pathways—MAP2K1—lung cancer	5.29e-06	1.85e-05	CbGpPWpGaD
Dopamine—HTR1A—Signaling Pathways—ERBB2—lung cancer	5.29e-06	1.85e-05	CbGpPWpGaD
Dopamine—CYP2D6—Metabolism—ERCC2—lung cancer	5.28e-06	1.85e-05	CbGpPWpGaD
Dopamine—CYP2C9—Metabolism—CYP1A1—lung cancer	5.28e-06	1.85e-05	CbGpPWpGaD
Dopamine—DRD1—Signaling Pathways—MMP9—lung cancer	5.28e-06	1.85e-05	CbGpPWpGaD
Dopamine—DRD4—Signaling Pathways—VEGFA—lung cancer	5.26e-06	1.84e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling Pathways—PIK3CD—lung cancer	5.26e-06	1.84e-05	CbGpPWpGaD
Dopamine—DRD1—Signaling Pathways—CDKN1A—lung cancer	5.26e-06	1.84e-05	CbGpPWpGaD
Dopamine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—lung cancer	5.26e-06	1.84e-05	CbGpPWpGaD
Dopamine—DRD1—Signaling Pathways—PTEN—lung cancer	5.25e-06	1.84e-05	CbGpPWpGaD
Dopamine—ADRB1—Signaling Pathways—CXCL8—lung cancer	5.24e-06	1.84e-05	CbGpPWpGaD
Dopamine—CYP2C9—Metabolism—ERCC2—lung cancer	5.24e-06	1.83e-05	CbGpPWpGaD
Dopamine—HTR1A—Signaling Pathways—MTOR—lung cancer	5.22e-06	1.83e-05	CbGpPWpGaD
Dopamine—HTR1A—Signaling Pathways—PIK3CB—lung cancer	5.22e-06	1.83e-05	CbGpPWpGaD
Dopamine—DRD4—Signaling Pathways—STAT3—lung cancer	5.21e-06	1.82e-05	CbGpPWpGaD
Dopamine—ADRB1—Signaling by GPCR—HRAS—lung cancer	5.21e-06	1.82e-05	CbGpPWpGaD
Dopamine—DRD2—GPCR downstream signaling—PIK3CA—lung cancer	5.21e-06	1.82e-05	CbGpPWpGaD
Dopamine—DRD3—Signaling Pathways—MMP9—lung cancer	5.21e-06	1.82e-05	CbGpPWpGaD
Dopamine—HTR7—Signaling Pathways—MAPK3—lung cancer	5.2e-06	1.82e-05	CbGpPWpGaD
Dopamine—DRD4—Signaling Pathways—NRAS—lung cancer	5.2e-06	1.82e-05	CbGpPWpGaD
Dopamine—DRD3—Signaling Pathways—CDKN1A—lung cancer	5.19e-06	1.82e-05	CbGpPWpGaD
Dopamine—CYP1A2—Metabolism—GSTP1—lung cancer	5.18e-06	1.81e-05	CbGpPWpGaD
Dopamine—DRD3—Signaling Pathways—PTEN—lung cancer	5.18e-06	1.81e-05	CbGpPWpGaD
Dopamine—DRD5—Signaling Pathways—HRAS—lung cancer	5.15e-06	1.8e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling by GPCR—KRAS—lung cancer	5.15e-06	1.8e-05	CbGpPWpGaD
Dopamine—SLC22A2—Metabolism—EP300—lung cancer	5.12e-06	1.79e-05	CbGpPWpGaD
Dopamine—DRD1—Signaling by GPCR—AKT1—lung cancer	5.12e-06	1.79e-05	CbGpPWpGaD
Dopamine—ADRB1—GPCR downstream signaling—AKT1—lung cancer	5.07e-06	1.77e-05	CbGpPWpGaD
Dopamine—HTR7—Signaling Pathways—MYC—lung cancer	5.06e-06	1.77e-05	CbGpPWpGaD
Dopamine—DRD3—Signaling by GPCR—AKT1—lung cancer	5.05e-06	1.77e-05	CbGpPWpGaD
Dopamine—CYP1A2—Metabolism—CAT—lung cancer	5.04e-06	1.77e-05	CbGpPWpGaD
Dopamine—ADRB1—Signaling Pathways—CASP3—lung cancer	5.02e-06	1.76e-05	CbGpPWpGaD
Dopamine—HTR1A—Signaling Pathways—CXCL8—lung cancer	5.02e-06	1.76e-05	CbGpPWpGaD
Dopamine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—lung cancer	5.01e-06	1.76e-05	CbGpPWpGaD
Dopamine—ADRB1—Signaling Pathways—IL2—lung cancer	5.01e-06	1.76e-05	CbGpPWpGaD
Dopamine—DRD1—Signaling Pathways—EP300—lung cancer	5e-06	1.75e-05	CbGpPWpGaD
Dopamine—SLC22A1—Metabolism—PTEN—lung cancer	5e-06	1.75e-05	CbGpPWpGaD
Dopamine—ADRB1—Signaling by GPCR—IL6—lung cancer	4.99e-06	1.75e-05	CbGpPWpGaD
Dopamine—HTR1A—Signaling by GPCR—HRAS—lung cancer	4.98e-06	1.75e-05	CbGpPWpGaD
Dopamine—DRD4—Signaling Pathways—MAPK3—lung cancer	4.98e-06	1.74e-05	CbGpPWpGaD
Dopamine—CYP2C19—Metabolism—APOA1—lung cancer	4.97e-06	1.74e-05	CbGpPWpGaD
Dopamine—HTR7—Signaling Pathways—EGFR—lung cancer	4.95e-06	1.73e-05	CbGpPWpGaD
Dopamine—DRD3—Signaling Pathways—EP300—lung cancer	4.94e-06	1.73e-05	CbGpPWpGaD
Dopamine—DRD5—Signaling Pathways—IL6—lung cancer	4.93e-06	1.73e-05	CbGpPWpGaD
Dopamine—SLC22A3—Metabolism—AKT1—lung cancer	4.93e-06	1.73e-05	CbGpPWpGaD
Dopamine—CYP1A2—Metabolism—ABCB1—lung cancer	4.9e-06	1.72e-05	CbGpPWpGaD
Dopamine—ADRB1—Signaling Pathways—CCND1—lung cancer	4.89e-06	1.71e-05	CbGpPWpGaD
Dopamine—ADRB1—Signaling Pathways—JUN—lung cancer	4.88e-06	1.71e-05	CbGpPWpGaD
Dopamine—DRD1—Signaling Pathways—SRC—lung cancer	4.86e-06	1.7e-05	CbGpPWpGaD
Dopamine—HTR1A—GPCR downstream signaling—AKT1—lung cancer	4.85e-06	1.7e-05	CbGpPWpGaD
Dopamine—DRD4—Signaling Pathways—MYC—lung cancer	4.84e-06	1.7e-05	CbGpPWpGaD
Dopamine—CYP1A2—Metabolism—TYMS—lung cancer	4.82e-06	1.69e-05	CbGpPWpGaD
Dopamine—HTR1A—Signaling Pathways—CASP3—lung cancer	4.8e-06	1.68e-05	CbGpPWpGaD
Dopamine—DRD3—Signaling Pathways—SRC—lung cancer	4.8e-06	1.68e-05	CbGpPWpGaD
Dopamine—HTR1A—Signaling Pathways—IL2—lung cancer	4.79e-06	1.68e-05	CbGpPWpGaD
Dopamine—SLC22A1—Metabolism—EP300—lung cancer	4.77e-06	1.67e-05	CbGpPWpGaD
Dopamine—HTR1A—Signaling by GPCR—IL6—lung cancer	4.77e-06	1.67e-05	CbGpPWpGaD
Dopamine—CYP1A2—Metabolism—GSTM1—lung cancer	4.76e-06	1.67e-05	CbGpPWpGaD
Dopamine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	4.76e-06	1.67e-05	CbGpPWpGaD
Dopamine—ADRB1—Signaling Pathways—MMP9—lung cancer	4.74e-06	1.66e-05	CbGpPWpGaD
Dopamine—DRD1—Signaling Pathways—VEGFA—lung cancer	4.74e-06	1.66e-05	CbGpPWpGaD
Dopamine—DRD4—Signaling Pathways—EGFR—lung cancer	4.74e-06	1.66e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling by GPCR—PIK3CA—lung cancer	4.73e-06	1.66e-05	CbGpPWpGaD
Dopamine—ADRB1—Signaling Pathways—CDKN1A—lung cancer	4.73e-06	1.66e-05	CbGpPWpGaD
Dopamine—ADRB1—Signaling Pathways—PTEN—lung cancer	4.72e-06	1.65e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling Pathways—MDM2—lung cancer	4.71e-06	1.65e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling Pathways—RAF1—lung cancer	4.69e-06	1.64e-05	CbGpPWpGaD
Dopamine—DRD1—Signaling Pathways—STAT3—lung cancer	4.69e-06	1.64e-05	CbGpPWpGaD
Dopamine—DRD1—Signaling Pathways—NRAS—lung cancer	4.68e-06	1.64e-05	CbGpPWpGaD
Dopamine—DRD3—Signaling Pathways—VEGFA—lung cancer	4.68e-06	1.64e-05	CbGpPWpGaD
Dopamine—HTR7—Signaling Pathways—KRAS—lung cancer	4.67e-06	1.64e-05	CbGpPWpGaD
Dopamine—HTR1A—Signaling Pathways—CCND1—lung cancer	4.67e-06	1.64e-05	CbGpPWpGaD
Dopamine—HTR1A—Signaling Pathways—JUN—lung cancer	4.66e-06	1.63e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling Pathways—ERBB2—lung cancer	4.64e-06	1.63e-05	CbGpPWpGaD
Dopamine—DRD3—Signaling Pathways—STAT3—lung cancer	4.63e-06	1.62e-05	CbGpPWpGaD
Dopamine—DRD3—Signaling Pathways—NRAS—lung cancer	4.62e-06	1.62e-05	CbGpPWpGaD
Dopamine—ADRB1—Signaling by GPCR—AKT1—lung cancer	4.6e-06	1.61e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling Pathways—MTOR—lung cancer	4.58e-06	1.61e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling Pathways—PIK3CB—lung cancer	4.58e-06	1.61e-05	CbGpPWpGaD
Dopamine—CYP2D6—Metabolism—APOA1—lung cancer	4.57e-06	1.6e-05	CbGpPWpGaD
Dopamine—DRD5—Signaling Pathways—AKT1—lung cancer	4.55e-06	1.59e-05	CbGpPWpGaD
Dopamine—HTR1A—Signaling Pathways—MMP9—lung cancer	4.54e-06	1.59e-05	CbGpPWpGaD
Dopamine—CYP2C19—Metabolism—PIK3CG—lung cancer	4.54e-06	1.59e-05	CbGpPWpGaD
Dopamine—CYP2C9—Metabolism—APOA1—lung cancer	4.53e-06	1.59e-05	CbGpPWpGaD
Dopamine—HTR1A—Signaling Pathways—CDKN1A—lung cancer	4.52e-06	1.58e-05	CbGpPWpGaD
Dopamine—CYP1A2—Metabolism—CYP1A1—lung cancer	4.51e-06	1.58e-05	CbGpPWpGaD
Dopamine—HTR1A—Signaling Pathways—PTEN—lung cancer	4.51e-06	1.58e-05	CbGpPWpGaD
Dopamine—ADRB1—Signaling Pathways—EP300—lung cancer	4.5e-06	1.57e-05	CbGpPWpGaD
Dopamine—DRD1—Signaling Pathways—MAPK3—lung cancer	4.48e-06	1.57e-05	CbGpPWpGaD
Dopamine—MAOA—Metabolism—PIK3CA—lung cancer	4.48e-06	1.57e-05	CbGpPWpGaD
Dopamine—CYP1A2—Metabolism—ERCC2—lung cancer	4.48e-06	1.57e-05	CbGpPWpGaD
Dopamine—DRD4—Signaling Pathways—KRAS—lung cancer	4.47e-06	1.57e-05	CbGpPWpGaD
Dopamine—DRD3—Signaling Pathways—MAPK3—lung cancer	4.42e-06	1.55e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling Pathways—CXCL8—lung cancer	4.4e-06	1.54e-05	CbGpPWpGaD
Dopamine—HTR1A—Signaling by GPCR—AKT1—lung cancer	4.4e-06	1.54e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling by GPCR—HRAS—lung cancer	4.38e-06	1.53e-05	CbGpPWpGaD
Dopamine—ADRB1—Signaling Pathways—SRC—lung cancer	4.37e-06	1.53e-05	CbGpPWpGaD
Dopamine—DRD1—Signaling Pathways—MYC—lung cancer	4.36e-06	1.53e-05	CbGpPWpGaD
Dopamine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	4.34e-06	1.52e-05	CbGpPWpGaD
Dopamine—CYP2C19—Metabolism—POMC—lung cancer	4.32e-06	1.51e-05	CbGpPWpGaD
Dopamine—HTR1A—Signaling Pathways—EP300—lung cancer	4.3e-06	1.51e-05	CbGpPWpGaD
Dopamine—DRD3—Signaling Pathways—MYC—lung cancer	4.3e-06	1.51e-05	CbGpPWpGaD
Dopamine—HTR7—Signaling Pathways—PIK3CA—lung cancer	4.29e-06	1.5e-05	CbGpPWpGaD
Dopamine—DRD1—Signaling Pathways—EGFR—lung cancer	4.26e-06	1.49e-05	CbGpPWpGaD
Dopamine—ADRB1—Signaling Pathways—VEGFA—lung cancer	4.26e-06	1.49e-05	CbGpPWpGaD
Dopamine—DRD2—GPCR downstream signaling—AKT1—lung cancer	4.25e-06	1.49e-05	CbGpPWpGaD
Dopamine—ADRB1—Signaling Pathways—STAT3—lung cancer	4.22e-06	1.48e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling Pathways—CASP3—lung cancer	4.22e-06	1.48e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling Pathways—IL2—lung cancer	4.21e-06	1.47e-05	CbGpPWpGaD
Dopamine—ADRB1—Signaling Pathways—NRAS—lung cancer	4.21e-06	1.47e-05	CbGpPWpGaD
Dopamine—DRD3—Signaling Pathways—EGFR—lung cancer	4.21e-06	1.47e-05	CbGpPWpGaD
Dopamine—CYP2C19—Metabolism—CREBBP—lung cancer	4.21e-06	1.47e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling by GPCR—IL6—lung cancer	4.19e-06	1.47e-05	CbGpPWpGaD
Dopamine—HTR1A—Signaling Pathways—SRC—lung cancer	4.18e-06	1.46e-05	CbGpPWpGaD
Dopamine—CYP2D6—Metabolism—PIK3CG—lung cancer	4.17e-06	1.46e-05	CbGpPWpGaD
Dopamine—HTR7—Signaling Pathways—TP53—lung cancer	4.15e-06	1.45e-05	CbGpPWpGaD
Dopamine—CYP2C9—Metabolism—PIK3CG—lung cancer	4.14e-06	1.45e-05	CbGpPWpGaD
Dopamine—DRD4—Signaling Pathways—PIK3CA—lung cancer	4.11e-06	1.44e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling Pathways—CCND1—lung cancer	4.1e-06	1.44e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling Pathways—JUN—lung cancer	4.09e-06	1.43e-05	CbGpPWpGaD
Dopamine—HTR1A—Signaling Pathways—VEGFA—lung cancer	4.07e-06	1.43e-05	CbGpPWpGaD
Dopamine—HTR1A—Signaling Pathways—STAT3—lung cancer	4.03e-06	1.41e-05	CbGpPWpGaD
Dopamine—ADRB1—Signaling Pathways—MAPK3—lung cancer	4.03e-06	1.41e-05	CbGpPWpGaD
Dopamine—DRD1—Signaling Pathways—KRAS—lung cancer	4.03e-06	1.41e-05	CbGpPWpGaD
Dopamine—HTR1A—Signaling Pathways—NRAS—lung cancer	4.02e-06	1.41e-05	CbGpPWpGaD
Dopamine—CYP2C19—Metabolism—PIK3CD—lung cancer	3.99e-06	1.4e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling Pathways—MMP9—lung cancer	3.98e-06	1.4e-05	CbGpPWpGaD
Dopamine—DRD4—Signaling Pathways—TP53—lung cancer	3.98e-06	1.39e-05	CbGpPWpGaD
Dopamine—DRD3—Signaling Pathways—KRAS—lung cancer	3.97e-06	1.39e-05	CbGpPWpGaD
Dopamine—HTR7—Signaling Pathways—HRAS—lung cancer	3.97e-06	1.39e-05	CbGpPWpGaD
Dopamine—CYP2D6—Metabolism—POMC—lung cancer	3.97e-06	1.39e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling Pathways—CDKN1A—lung cancer	3.97e-06	1.39e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling Pathways—PTEN—lung cancer	3.96e-06	1.39e-05	CbGpPWpGaD
Dopamine—CYP2C9—Metabolism—POMC—lung cancer	3.94e-06	1.38e-05	CbGpPWpGaD
Dopamine—CYP2C19—Metabolism—ALB—lung cancer	3.94e-06	1.38e-05	CbGpPWpGaD
Dopamine—ADRB1—Signaling Pathways—MYC—lung cancer	3.92e-06	1.37e-05	CbGpPWpGaD
Dopamine—CYP1A2—Metabolism—APOA1—lung cancer	3.87e-06	1.36e-05	CbGpPWpGaD
Dopamine—CYP2D6—Metabolism—CREBBP—lung cancer	3.87e-06	1.35e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling by GPCR—AKT1—lung cancer	3.86e-06	1.35e-05	CbGpPWpGaD
Dopamine—HTR1A—Signaling Pathways—MAPK3—lung cancer	3.85e-06	1.35e-05	CbGpPWpGaD
Dopamine—CYP2C9—Metabolism—CREBBP—lung cancer	3.84e-06	1.34e-05	CbGpPWpGaD
Dopamine—ADRB1—Signaling Pathways—EGFR—lung cancer	3.83e-06	1.34e-05	CbGpPWpGaD
Dopamine—DRD4—Signaling Pathways—HRAS—lung cancer	3.8e-06	1.33e-05	CbGpPWpGaD
Dopamine—HTR7—Signaling Pathways—IL6—lung cancer	3.8e-06	1.33e-05	CbGpPWpGaD
Dopamine—SLC22A2—Metabolism—PIK3CA—lung cancer	3.79e-06	1.33e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling Pathways—EP300—lung cancer	3.78e-06	1.32e-05	CbGpPWpGaD
Dopamine—HTR1A—Signaling Pathways—MYC—lung cancer	3.75e-06	1.31e-05	CbGpPWpGaD
Dopamine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	3.71e-06	1.3e-05	CbGpPWpGaD
Dopamine—DRD1—Signaling Pathways—PIK3CA—lung cancer	3.7e-06	1.3e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling Pathways—SRC—lung cancer	3.67e-06	1.29e-05	CbGpPWpGaD
Dopamine—CYP2D6—Metabolism—PIK3CD—lung cancer	3.67e-06	1.28e-05	CbGpPWpGaD
Dopamine—HTR1A—Signaling Pathways—EGFR—lung cancer	3.67e-06	1.28e-05	CbGpPWpGaD
Dopamine—MAOA—Metabolism—AKT1—lung cancer	3.66e-06	1.28e-05	CbGpPWpGaD
Dopamine—DRD3—Signaling Pathways—PIK3CA—lung cancer	3.65e-06	1.28e-05	CbGpPWpGaD
Dopamine—DRD4—Signaling Pathways—IL6—lung cancer	3.64e-06	1.27e-05	CbGpPWpGaD
Dopamine—CYP2C9—Metabolism—PIK3CD—lung cancer	3.64e-06	1.27e-05	CbGpPWpGaD
Dopamine—ADRB1—Signaling Pathways—KRAS—lung cancer	3.62e-06	1.27e-05	CbGpPWpGaD
Dopamine—CYP2D6—Metabolism—ALB—lung cancer	3.62e-06	1.27e-05	CbGpPWpGaD
Dopamine—CYP2C9—Metabolism—ALB—lung cancer	3.59e-06	1.26e-05	CbGpPWpGaD
Dopamine—DRD1—Signaling Pathways—TP53—lung cancer	3.58e-06	1.25e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling Pathways—VEGFA—lung cancer	3.58e-06	1.25e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling Pathways—STAT3—lung cancer	3.54e-06	1.24e-05	CbGpPWpGaD
Dopamine—CYP1A2—Metabolism—PIK3CG—lung cancer	3.54e-06	1.24e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling Pathways—NRAS—lung cancer	3.53e-06	1.24e-05	CbGpPWpGaD
Dopamine—DRD3—Signaling Pathways—TP53—lung cancer	3.53e-06	1.24e-05	CbGpPWpGaD
Dopamine—SLC22A1—Metabolism—PIK3CA—lung cancer	3.53e-06	1.24e-05	CbGpPWpGaD
Dopamine—HTR7—Signaling Pathways—AKT1—lung cancer	3.51e-06	1.23e-05	CbGpPWpGaD
Dopamine—CYP2C19—Metabolism—PIK3CB—lung cancer	3.48e-06	1.22e-05	CbGpPWpGaD
Dopamine—HTR1A—Signaling Pathways—KRAS—lung cancer	3.46e-06	1.21e-05	CbGpPWpGaD
Dopamine—CYP2C19—Metabolism—PTGS2—lung cancer	3.44e-06	1.21e-05	CbGpPWpGaD
Dopamine—DRD1—Signaling Pathways—HRAS—lung cancer	3.42e-06	1.2e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling Pathways—MAPK3—lung cancer	3.38e-06	1.19e-05	CbGpPWpGaD
Dopamine—DRD3—Signaling Pathways—HRAS—lung cancer	3.38e-06	1.18e-05	CbGpPWpGaD
Dopamine—CYP1A2—Metabolism—POMC—lung cancer	3.36e-06	1.18e-05	CbGpPWpGaD
Dopamine—DRD4—Signaling Pathways—AKT1—lung cancer	3.36e-06	1.18e-05	CbGpPWpGaD
Dopamine—ADRB1—Signaling Pathways—PIK3CA—lung cancer	3.33e-06	1.17e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling Pathways—MYC—lung cancer	3.29e-06	1.15e-05	CbGpPWpGaD
Dopamine—CYP1A2—Metabolism—CREBBP—lung cancer	3.28e-06	1.15e-05	CbGpPWpGaD
Dopamine—DRD1—Signaling Pathways—IL6—lung cancer	3.28e-06	1.15e-05	CbGpPWpGaD
Dopamine—DRD3—Signaling Pathways—IL6—lung cancer	3.23e-06	1.13e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling Pathways—EGFR—lung cancer	3.22e-06	1.13e-05	CbGpPWpGaD
Dopamine—ADRB1—Signaling Pathways—TP53—lung cancer	3.22e-06	1.13e-05	CbGpPWpGaD
Dopamine—CYP2D6—Metabolism—PIK3CB—lung cancer	3.2e-06	1.12e-05	CbGpPWpGaD
Dopamine—HTR1A—Signaling Pathways—PIK3CA—lung cancer	3.18e-06	1.11e-05	CbGpPWpGaD
Dopamine—CYP2C9—Metabolism—PIK3CB—lung cancer	3.17e-06	1.11e-05	CbGpPWpGaD
Dopamine—CYP2D6—Metabolism—PTGS2—lung cancer	3.17e-06	1.11e-05	CbGpPWpGaD
Dopamine—CYP2C9—Metabolism—PTGS2—lung cancer	3.14e-06	1.1e-05	CbGpPWpGaD
Dopamine—CYP1A2—Metabolism—PIK3CD—lung cancer	3.11e-06	1.09e-05	CbGpPWpGaD
Dopamine—SLC22A2—Metabolism—AKT1—lung cancer	3.09e-06	1.08e-05	CbGpPWpGaD
Dopamine—HTR1A—Signaling Pathways—TP53—lung cancer	3.08e-06	1.08e-05	CbGpPWpGaD
Dopamine—ADRB1—Signaling Pathways—HRAS—lung cancer	3.08e-06	1.08e-05	CbGpPWpGaD
Dopamine—CYP1A2—Metabolism—ALB—lung cancer	3.07e-06	1.07e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling Pathways—KRAS—lung cancer	3.04e-06	1.06e-05	CbGpPWpGaD
Dopamine—DRD1—Signaling Pathways—AKT1—lung cancer	3.02e-06	1.06e-05	CbGpPWpGaD
Dopamine—CYP2C19—Metabolism—PTEN—lung cancer	3e-06	1.05e-05	CbGpPWpGaD
Dopamine—DRD3—Signaling Pathways—AKT1—lung cancer	2.98e-06	1.04e-05	CbGpPWpGaD
Dopamine—ADRB1—Signaling Pathways—IL6—lung cancer	2.95e-06	1.03e-05	CbGpPWpGaD
Dopamine—HTR1A—Signaling Pathways—HRAS—lung cancer	2.94e-06	1.03e-05	CbGpPWpGaD
Dopamine—SLC22A1—Metabolism—AKT1—lung cancer	2.88e-06	1.01e-05	CbGpPWpGaD
Dopamine—CYP2C19—Metabolism—EP300—lung cancer	2.86e-06	1e-05	CbGpPWpGaD
Dopamine—HTR1A—Signaling Pathways—IL6—lung cancer	2.82e-06	9.87e-06	CbGpPWpGaD
Dopamine—DRD2—Signaling Pathways—PIK3CA—lung cancer	2.79e-06	9.78e-06	CbGpPWpGaD
Dopamine—CYP2D6—Metabolism—PTEN—lung cancer	2.76e-06	9.68e-06	CbGpPWpGaD
Dopamine—CYP2C9—Metabolism—PTEN—lung cancer	2.74e-06	9.59e-06	CbGpPWpGaD
Dopamine—ADRB1—Signaling Pathways—AKT1—lung cancer	2.72e-06	9.52e-06	CbGpPWpGaD
Dopamine—CYP1A2—Metabolism—PIK3CB—lung cancer	2.71e-06	9.49e-06	CbGpPWpGaD
Dopamine—DRD2—Signaling Pathways—TP53—lung cancer	2.7e-06	9.47e-06	CbGpPWpGaD
Dopamine—CYP1A2—Metabolism—PTGS2—lung cancer	2.68e-06	9.4e-06	CbGpPWpGaD
Dopamine—CYP2D6—Metabolism—EP300—lung cancer	2.63e-06	9.23e-06	CbGpPWpGaD
Dopamine—CYP2C9—Metabolism—EP300—lung cancer	2.61e-06	9.15e-06	CbGpPWpGaD
Dopamine—HTR1A—Signaling Pathways—AKT1—lung cancer	2.6e-06	9.1e-06	CbGpPWpGaD
Dopamine—DRD2—Signaling Pathways—HRAS—lung cancer	2.59e-06	9.05e-06	CbGpPWpGaD
Dopamine—DRD2—Signaling Pathways—IL6—lung cancer	2.47e-06	8.66e-06	CbGpPWpGaD
Dopamine—CYP1A2—Metabolism—PTEN—lung cancer	2.34e-06	8.2e-06	CbGpPWpGaD
Dopamine—DRD2—Signaling Pathways—AKT1—lung cancer	2.28e-06	7.99e-06	CbGpPWpGaD
Dopamine—CYP1A2—Metabolism—EP300—lung cancer	2.23e-06	7.82e-06	CbGpPWpGaD
Dopamine—CYP2C19—Metabolism—PIK3CA—lung cancer	2.12e-06	7.42e-06	CbGpPWpGaD
Dopamine—CYP2D6—Metabolism—PIK3CA—lung cancer	1.95e-06	6.83e-06	CbGpPWpGaD
Dopamine—CYP2C9—Metabolism—PIK3CA—lung cancer	1.93e-06	6.77e-06	CbGpPWpGaD
Dopamine—CYP2C19—Metabolism—AKT1—lung cancer	1.73e-06	6.06e-06	CbGpPWpGaD
Dopamine—CYP1A2—Metabolism—PIK3CA—lung cancer	1.65e-06	5.78e-06	CbGpPWpGaD
Dopamine—CYP2D6—Metabolism—AKT1—lung cancer	1.59e-06	5.58e-06	CbGpPWpGaD
Dopamine—CYP2C9—Metabolism—AKT1—lung cancer	1.58e-06	5.53e-06	CbGpPWpGaD
Dopamine—CYP1A2—Metabolism—AKT1—lung cancer	1.35e-06	4.72e-06	CbGpPWpGaD
